You are here

Approvals, Launches, and New Indications

However, patent dispute will delay one launch
Approval acquired through tropical disease priority review voucher program
Therapy approved for adults and children with refractory PMBCL or who have relapsed after two or more prior lines of therapy
Continuous nerve stimulation helps to alleviate withdrawal symptoms
Agent decreases the chance of infection due to chemo-induced febrile neutropenia
Drug now approved for moderately to severely active ulcerative colitis
Novel enzyme therapy is for adults with PKU who have uncontrolled blood phenylalanine concentrations with current treatment
Drug indicated for use prior to surgery to boost platelet counts
Novel drug is a first-in-class treatment that reduces migraine occurrence
Lucemyra indicated for up to 14 days as part of a long-term treatment plan